Skip to content

Boosted PIs superior to no PIs as salvage therapy in highly PI-experienced

Can atazanavir reverse body fat changes?

Meta-analysis finds PI-based HAART better than NNRTI regimens in NRTI experienced

More bad news on tenofovir/abacavir/3TC

Minority can have CD4 rises and no illness for more than 3 years after treatment failure

Gastrointestinal side-effects lead one in eight to change HAART regimen in first year of treatment

NNRTI patients switched to Trizivir show lipid improvements

Atazanavir/ritonavir comparable to lopinavir/ritonavir in PI-experienced

Switch from d4T to abacavir gives `modest` fat gains